Bellvitge Biomedical Research Institute: research centre for cancer, neurosciences and translational medicine

Authors

  • Gabriel Capellá Bellvitge Biomedical Research Institute (IDIBELL). Gran Via de l’Hospitalet 199, 08908 L’Hospitalet de Llobregat, Barcelona

Keywords:

IDIBELL, Cancer, Neuroscience, Translational Medicine, Bellvitge.

Abstract

The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center for cancer, neurosciences and translational medicine established in 2004 in L’Hospitalet de Llobregat, south of Barcelona. Its local partners are the Bellvitge University Hospital (HUB) and the Viladecans Hospital, both part of the Catalan Institute of Health (ICS), the Catalan Institute of Oncology (ICO), the University of Barcelona (UB) and the town council of L’Hospitalet de Llobregat. In 2009, it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Institute of Health. IDIBELL also carries out high-level basic, epidemiological, translational and clinical research though three areas and nine research programs, aiming at an effective translation of scientific advances into the prevention, diagnosis, prognosis and treatment of health problems and promoting innovation in health research.

Keywords: IDIBELL, Cancer, Neuroscience, Translational Medicine, Bellvitge.

Author Biography

Gabriel Capellá, Bellvitge Biomedical Research Institute (IDIBELL). Gran Via de l’Hospitalet 199, 08908 L’Hospitalet de Llobregat, Barcelona

Downloads

Issue

Vol. 13 No. 1 (2017)

Section

Research reviews

License

This work is subject, unless the contrary is indicated in the text, the photographs or in other illustrations, to an Attribution —Non-
Commercial— No Derivative Works 3.0 Creative Commons License, the full text of which can be consulted at http://creativecommons.org/licenses/by-nc-nd/3.0/. You are free to share, copy, distribute and transmit the work provided that the author is credited and reuse of the material is restricted to non-commercial purposes only and that no derivative works are created from the original material.